Literature DB >> 15186706

Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice.

Matthew T Davis1, Wally J Bartfay.   

Abstract

Chronic iron overload is a major cause of cardiac failure throughout the world, but its pathogenesis remains to be clarified. It is conjectured that the toxicity of iron is due to its ability to catalyze the formation of oxygen free radicals (OFR), which can damage cellular membranes, proteins, and DNA. The authors report on the cardioprotective effects of the glutathione peroxidase (GPx) mimic ebselen on iron concentrations in the heart and GPx activity, and on the production of the cytotoxic aldehydes hexanal, 4-hydroxyl-2-nonenal (HNE), and malondialdehyde (MDA). Fifteen B6D2F1 mice were randomized to 1 of 3 treatment groups for a total of 20 treatments: 1) control (0.1 mL normal saline i.p. per mouse, per day); 2) iron-only (10 mg iron dextran i.p. per mouse, per day); 3) iron plus ebselen (25 mg/kg p.o. per mouse, per day). In comparison to iron-only treated mice, the authors' findings show that supplementation with ebselen can decrease both cytotoxic aldehyde and iron concentrations in heart tissue. Additionally, mice supplemented with ebselen had an increase in GPx activity level in comparison to iron-only treated mice. To the authors' knowledge, this is the first study to examine the cardioprotective effects of ebselen against OFR damage in a model of chronic iron overload. These findings suggest that ebselen may have significance in the management of disorders of iron overload.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186706     DOI: 10.1177/1099800403261350

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  9 in total

Review 1.  Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.

Authors:  Gajendra Kumar Azad; Raghuvir S Tomar
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

Review 2.  Pharmacology of iron transport.

Authors:  Shaina L Byrne; Divya Krishnamurthy; Marianne Wessling-Resnick
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

3.  Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake.

Authors:  Herbert A Wetli; Peter D Buckett; Marianne Wessling-Resnick
Journal:  Chem Biol       Date:  2006-09

Review 4.  Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.

Authors:  Richard Gordan; Suwakon Wongjaikam; Judith K Gwathmey; Nipon Chattipakorn; Siriporn C Chattipakorn; Lai-Hua Xie
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

5.  Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Authors:  Phyllis Chew; Derek Y C Yuen; Nada Stefanovic; Josefa Pete; Melinda T Coughlan; Karin A Jandeleit-Dahm; Merlin C Thomas; Franklin Rosenfeldt; Mark E Cooper; Judy B de Haan
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

Review 6.  The Central Role of Biometals Maintains Oxidative Balance in the Context of Metabolic and Neurodegenerative Disorders.

Authors:  Michal Pokusa; Alžbeta Kráľová Trančíková
Journal:  Oxid Med Cell Longev       Date:  2017-07-02       Impact factor: 6.543

7.  Hepcidin Promoted Ferroptosis through Iron Metabolism which Is Associated with DMT1 Signaling Activation in Early Brain Injury following Subarachnoid Hemorrhage.

Authors:  Hongxia Zhang; Robert Ostrowski; Dengzhi Jiang; Qing Zhao; Yidan Liang; Xudong Che; Jun Zhao; Xiang Xiang; Wang Qin; Zhaohui He
Journal:  Oxid Med Cell Longev       Date:  2021-12-27       Impact factor: 6.543

Review 8.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

9.  Amino acids and fatty acids in patients with beta thalassemia major.

Authors:  Tugba Koca; Duran Canatan; Ahmet Rifat Örmeci; Yavuz Savas Koca; Handan Duman; Aslı Baykal; Mustafa Akcam
Journal:  Acta Biomed       Date:  2020-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.